Z.N.A. Stuivenberg Ziekenhuis
Welcome,         Profile    Billing    Logout  
 4 Trials 
12 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wu, Ka Lung
Predictor2, NCT03887156: Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft

Recruiting
2/3
227
Europe
Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
Assistance Publique - Hôpitaux de Paris, SATT, SNC Graft Versus Host Disease, Imagine Institute, Axonal-Biostatem, CERBA laboratory
Acute Myeloid Leukemia in Remission, Lymphoma in Remission, Non-progressive Myeloproliferative Syndrome, Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts, Acute Leukemia Biphenotypic in Remission, Acute Lymphoblastic Leukemia
03/23
03/23
LINKER-MM1, NCT03761108 / 2018-003188-78: Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma

Checkmark Presentation of data from LINKER-MM1 trial in heavily pre-treated multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from LINKER-MM1 trial in heavily pre-treated multiple myeloma at ASH 2022
Checkmark Completion of enrollment of trial for r/r multiple myeloma
Dec 2022 - Dec 2022: Completion of enrollment of trial for r/r multiple myeloma
Checkmark Data from P1 portion of P1/2 trial for multiple myeloma at ASH 2021
More
Recruiting
1/2
387
Europe, Japan, US, RoW
Linvoseltamab, REGN5458
Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc.
Multiple Myeloma
05/32
06/32
NCT05839626: A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

Terminated
1/2
32
Europe, RoW
SAR445514
Sanofi
Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis
05/25
05/25
Granacher, Nikki CP
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Hourglass Jun 2025 - Jun 2025 : 72-week follow-up with long-term efficacy outcomes data for JAK-naive MF
Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Exclusivity expiry in US
More
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
NCT06401356: An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Recruiting
3
50
Europe, US
Pelabresib, CPI-0610
Novartis Pharmaceuticals
Hematologic Malignancy, Solid Tumor, Advanced Malignancies
06/27
06/27
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
Predictor2, NCT03887156: Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft

Recruiting
2/3
227
Europe
Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
Assistance Publique - Hôpitaux de Paris, SATT, SNC Graft Versus Host Disease, Imagine Institute, Axonal-Biostatem, CERBA laboratory
Acute Myeloid Leukemia in Remission, Lymphoma in Remission, Non-progressive Myeloproliferative Syndrome, Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts, Acute Leukemia Biphenotypic in Remission, Acute Lymphoblastic Leukemia
03/23
03/23
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
Breems, Dimitri A
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
Predictor2, NCT03887156: Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft

Recruiting
2/3
227
Europe
Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
Assistance Publique - Hôpitaux de Paris, SATT, SNC Graft Versus Host Disease, Imagine Institute, Axonal-Biostatem, CERBA laboratory
Acute Myeloid Leukemia in Remission, Lymphoma in Remission, Non-progressive Myeloproliferative Syndrome, Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts, Acute Leukemia Biphenotypic in Remission, Acute Lymphoblastic Leukemia
03/23
03/23
BYON4413.001, NCT06359002: Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

Recruiting
1
100
Europe
BYON4413
Byondis B.V.
Relapsed / Refractory AML, Relapsed / Refractory MDS
12/26
03/27
Eyckmans, Tom
Predictor2, NCT03887156: Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft

Recruiting
2/3
227
Europe
Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
Assistance Publique - Hôpitaux de Paris, SATT, SNC Graft Versus Host Disease, Imagine Institute, Axonal-Biostatem, CERBA laboratory
Acute Myeloid Leukemia in Remission, Lymphoma in Remission, Non-progressive Myeloproliferative Syndrome, Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts, Acute Leukemia Biphenotypic in Remission, Acute Lymphoblastic Leukemia
03/23
03/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wu, Ka Lung
Predictor2, NCT03887156: Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft

Recruiting
2/3
227
Europe
Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
Assistance Publique - Hôpitaux de Paris, SATT, SNC Graft Versus Host Disease, Imagine Institute, Axonal-Biostatem, CERBA laboratory
Acute Myeloid Leukemia in Remission, Lymphoma in Remission, Non-progressive Myeloproliferative Syndrome, Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts, Acute Leukemia Biphenotypic in Remission, Acute Lymphoblastic Leukemia
03/23
03/23
LINKER-MM1, NCT03761108 / 2018-003188-78: Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma

Checkmark Presentation of data from LINKER-MM1 trial in heavily pre-treated multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from LINKER-MM1 trial in heavily pre-treated multiple myeloma at ASH 2022
Checkmark Completion of enrollment of trial for r/r multiple myeloma
Dec 2022 - Dec 2022: Completion of enrollment of trial for r/r multiple myeloma
Checkmark Data from P1 portion of P1/2 trial for multiple myeloma at ASH 2021
More
Recruiting
1/2
387
Europe, Japan, US, RoW
Linvoseltamab, REGN5458
Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc.
Multiple Myeloma
05/32
06/32
NCT05839626: A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

Terminated
1/2
32
Europe, RoW
SAR445514
Sanofi
Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis
05/25
05/25
Granacher, Nikki CP
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Hourglass Jun 2025 - Jun 2025 : 72-week follow-up with long-term efficacy outcomes data for JAK-naive MF
Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Exclusivity expiry in US
More
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
NCT06401356: An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Recruiting
3
50
Europe, US
Pelabresib, CPI-0610
Novartis Pharmaceuticals
Hematologic Malignancy, Solid Tumor, Advanced Malignancies
06/27
06/27
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
Predictor2, NCT03887156: Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft

Recruiting
2/3
227
Europe
Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
Assistance Publique - Hôpitaux de Paris, SATT, SNC Graft Versus Host Disease, Imagine Institute, Axonal-Biostatem, CERBA laboratory
Acute Myeloid Leukemia in Remission, Lymphoma in Remission, Non-progressive Myeloproliferative Syndrome, Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts, Acute Leukemia Biphenotypic in Remission, Acute Lymphoblastic Leukemia
03/23
03/23
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
Breems, Dimitri A
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
Predictor2, NCT03887156: Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft

Recruiting
2/3
227
Europe
Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
Assistance Publique - Hôpitaux de Paris, SATT, SNC Graft Versus Host Disease, Imagine Institute, Axonal-Biostatem, CERBA laboratory
Acute Myeloid Leukemia in Remission, Lymphoma in Remission, Non-progressive Myeloproliferative Syndrome, Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts, Acute Leukemia Biphenotypic in Remission, Acute Lymphoblastic Leukemia
03/23
03/23
BYON4413.001, NCT06359002: Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

Recruiting
1
100
Europe
BYON4413
Byondis B.V.
Relapsed / Refractory AML, Relapsed / Refractory MDS
12/26
03/27
Eyckmans, Tom
Predictor2, NCT03887156: Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft

Recruiting
2/3
227
Europe
Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
Assistance Publique - Hôpitaux de Paris, SATT, SNC Graft Versus Host Disease, Imagine Institute, Axonal-Biostatem, CERBA laboratory
Acute Myeloid Leukemia in Remission, Lymphoma in Remission, Non-progressive Myeloproliferative Syndrome, Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts, Acute Leukemia Biphenotypic in Remission, Acute Lymphoblastic Leukemia
03/23
03/23

Download Options